HIV/AIDS

Archived Vaccines Reports and Articles

• Assaying Potency of Novel Vaccines

• Vaccine Cell Substrate 2004

• National AIDS Vaccine Advocates Forum

• The Science of Team Science—Assessing the Value of Transdisciplinary Research, October 30 – 31, 2006

• Keystone Symposia 2007—Intensified Efforts toward HIV Vaccines

• AIDS Vaccine 2007 - Exploring New Pathways to HIV Vaccines

Journal Articles and Publications by DAIDS/NIAID Staff

• Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J, Working Group convened by the Global HIV Vaccine Enterprise. Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions. PLoS Med. 4 (12): e348, 2007.
• Johnston MI, Fauci AS. An HIV Vaccine—Evolving Concepts. N Engl J Med. 356 (20): 2073-2081, 2007.
• What Can We Expect from the First AIDS Vaccine? (Commentary in San Francisco Chronicle, co-authored by Drs. Anthony S. Fauci and Margaret I. Johnston)
• Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 46 (2): 222-230, 2007.
• Lau CY, Velasco PP, Johnston MI. A New Era in HIV Vaccine Development. Expert Rev Anti Infect Ther. 5 (2): 205-15, 2007.
• Johnston, MI, Fauci, AS. What Can We Expect from the First AIDS Vaccine? San Francisco Chronicle, May 18, 2007.
• Rodriguez-Chavez IR, Allen M, Hill EL, Sheets RL, Pensiero M, Bradac JA, D'Souza MP. Current Advances and Challenges in HIV-1 Vaccines. Curr HIV/AIDS Rep. 3 (1): 39-47, 2006.
• Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwenda N, Taha T, Karim SA, Flores J, Sheppard HW.
  Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. AIDS Res Hum Retroviruses. 21 (4): 285-291, 2005.
• Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. Recommendations for the Design and Use of Standard Virus Panels to Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. J Virol. 79 (16): 10103-10107, 2005.
• Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, Hayes P, Birungi J, Anzala O, Garcia M, Harari A, Frank I, Baydo R, Baker M, Holbrook J, Ottinger J, Lamoreaux L, Epling CL, Sinclair E, Suni MA, Punt K, Calarota S, El-Bahi S, Alter G, Maila H, Kuta E, Cox J, Gray C, Altfeld M, Nougarede N, Boyer J, Tussey L, Tobery T, Bredt B, Roederer M, Koup R, Maino VC, Weinhold K, Pantaleo G, Gilmour J, Horton H, Sekaly RP. Standardization of Cytokine Flow Cytometry Assays. BMC Immunol. 6: 13, 2005.
• Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguía M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 40 (5): 617-624, 2005.
• Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L; NIAID HIV Vaccine Trials Network. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 192 (7): 1249-1259, 2005.
• D'Souza MP, Allen M, Sheets R, Johnston MI. Current Advances in HIV Vaccines. Curr HIV/AIDS Rep. 1 (1): 18-24, 2004.
• Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine. 21 (21-22): 2933-2947, 2003.
• Tramont EC, Johnston MI. Progress in the Development of an HIV Vaccine. Expert Opin Emerg Drugs. 8 (1): 37-45, 2003.
• Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, Haynes BF, Baltimore D, Collins C, Douglas RG, Esparza J, Francis DP, Ganguly NK, Gerberding JL, Johnston MI, Kazatchkine MD, McMichael AJ, Makgoba MW, Pantaleo G, Piot P, Shao Y, Tramont E, Varmus H, Wasserheit JN. Medicine. The Need for a Global HIV Vaccine Enterprise. Science. 300 (5628): 2036-2039, 2003.
• Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, Allen M, McDougal JS. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis. 187 (6): 879-886, 2003.
• Warren J. Preclinical AIDS Vaccine Research: Survey of SIV, SHIV, and HIV Challenge Studies in Vaccinated Nonhuman Primates. J Med Primatol. 31 (4-5): 237-56, 2002.
• Graham BS. Clinical Trials of HIV Vaccines. Annu Rev Med. 53: 207-221, 2002.

• D'Souza MP, Allen MA, Johnston MI. HIV Vaccines: Biological and Clinical Considerations. Curr Infect Dis Rep. 4 (4): 359-368, 2002.
• Shapiro SZ. The HIV/AIDS Vaccine Researchers' Orientation to the Process of Preparing a US FDA Application for an Investigational New Drug (IND): What It Is All about and How You Start by Preparing for Your Pre-IND Meeting. Vaccine. 20: 1261-1280, 2001.

• Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses. 17 (8): 667-674, 2001.
• Flores J, Johnston MI. Progress in HIV Vaccine Development. Curr Opin Pharmacol. 1 (5): 504-510, 2001. Baltimore D, Heilman C. HIV Vaccines: Prospects and Challenges. Sci Am. 279 (1): 98-103, 1998. Heilman CA, Baltimore D. HIV Vaccines—Where Are We Going? (PDF). Nature Medicine. 4 (5 Suppl): 532-534, 1998.  
  
  
back to top